1674-62-0

Basic information

• Product Name: METFORMIN RELATED COMPOUND B (25 MG) (1-METHYLBIGUANIDE HYDROCHLORIDE)
• Synonyms: 1-methylbiguanidehydrochloride;1-methyl-biguanidmonohydrochloride;1-metilbiguanidecloridrato;MetforMin Related CoMpound B;N'-Methylbiguanide monohydrochloride;1-Methylbiguanide hyrdochloride (Metformin RCB);1-Methylbiguanide monohydrochloride;METFORMIN RELATED COMPOUND B (25 MG) (1-METHYLBIGUANIDE HYDROCHLORIDE)
• CAS NO: 1674-62-0
• Molecular Formula: C₃H₉N₅*ClH
• Molecular Weight: 151.598
• Mol File: 1674-62-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 225 °C at 760 mmHg
• Flash Point: 89.9 °C
• Appearance: /
• Density: 1.45 g/cm³
• Vapor Pressure: 0.00154mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Methanol (Slightly), Water (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: METFORMIN RELATED COMPOUND B (25 MG) (1-METHYLBIGUANIDE HYDROCHLORIDE)(CAS DataBase Reference)
• NIST Chemistry Reference: METFORMIN RELATED COMPOUND B (25 MG) (1-METHYLBIGUANIDE HYDROCHLORIDE)(1674-62-0)
• EPA Substance Registry System: METFORMIN RELATED COMPOUND B (25 MG) (1-METHYLBIGUANIDE HYDROCHLORIDE)(1674-62-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1674-62-0(Hazardous Substances Data)

Usage

Uses

1-Methylbiguanide Hydrochloride (Metformin USP Related Compound B) is a compound similar to Metformin Hydrochloride (M258815), an oral hypogylcemic agent.

InChI:InChI=1/C3H9N5/c1-7-3(6)8-2(4)5/h1H3,(H6,4,5,6,7,8)

Synthetic route

methylamine hydrochloride (593-51-1) + N-Cyanoguanidine (127099-85-8, 780722-26-1) → N1-methyl biguanide hydrochloride (1674-62-0)

Conditions	Yield
In butan-1-ol for 15h; Reflux;	61%

N1-methyl biguanide hydrochloride (1674-62-0) + methyl (1,3-benzothiazol-2-ylsulfanyl)acetate (24044-87-9) → 6-(benzothiazol-2-ylsulfanylmethyl)-N-methyl-[1,3,5]triazine-2,4-diamine

Conditions	Yield
Stage #1: N1-methyl biguanide hydrochloride With sodium methylate In methanol at 20℃; for 0.5h; Stage #2: methyl (1,3-benzothiazol-2-ylsulfanyl)acetate In methanol for 10h; Heating;	73%

methylamine hydrochloride (593-51-1) + N1-methyl biguanide hydrochloride (1674-62-0) → 1-methylguanidine (471-29-4) + guanidine nitrate (113-00-8)

Conditions	Yield
beim Erhitzen;

N1-methyl biguanide hydrochloride (1674-62-0) → CYANAMID (420-04-2) + 1-methylguanidine (471-29-4) + guanidine hydrochloride (50-01-1) + methylcyanamide (4674-68-4)

Conditions	Yield
bei der thermischen Zersetzung;

ammonium chloride + N1-methyl biguanide hydrochloride (1674-62-0) → 1-methylguanidine (471-29-4) + guanidine nitrate (113-00-8)

Conditions	Yield
beim Erhitzen;

Upstream product

• 593-51-1 methylamine hydrochloride 
• 127099-85-8 N-Cyanoguanidine 

Downstream Products

• 471-29-4 1-methylguanidine 
• 113-00-8 guanidine nitrate 
• 420-04-2 CYANAMID 
• 50-01-1 guanidine hydrochloride 
• 4674-68-4 methylcyanamide 

Relevant articles and documents

BIGUANIDE COMPOUND AND USE THEREOF

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.